Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D9PBQ8
|
|||
| Drug Name |
PF-04859989
|
|||
| Synonyms |
(3S)-3-amino-1-hydroxy-1,2,3,4-tetrahydroquinolin-2-one; (S)-3-Amino-1-hydroxy-3,4-dihydroquinolin-2(1H)-one; CHEMBL2047851; 34783-48-7 (free base); 34783-48-7; (3S)-3-amino-1-hydroxy-3,4-dihydroquinolin-2-one; GTPL9038; SCHEMBL2132616; ZINC6117343; BDBM50386292; AKOS006281463; compound 1 [PMID: 23466229]; NCGC00485082-01; Q27088318; (3s)-3-amino-1-hydroxy-3,4-dihydroquinolin-2(1h)-one; Z1601186413
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cognitive impairment [ICD-11: 6D71; ICD-10: F06.7; ICD-9: 331.83] | Preclinical | [1] | |
| Schizophrenia [ICD-11: 6A20] | Preclinical | [1] | ||
| Company |
Pfizer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C9H10N2O2
|
|||
| Canonical SMILES |
C1C(C(=O)N(C2=CC=CC=C21)O)N
|
|||
| InChI |
1S/C9H10N2O2/c10-7-5-6-3-1-2-4-8(6)11(13)9(7)12/h1-4,7,13H,5,10H2/t7-/m0/s1
|
|||
| InChIKey |
HYTRYTZFJVVZAF-ZETCQYMHSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Kynurenine oxoglutarate transaminase II (AADAT) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019 May;18(5):379-401. | |||
| REF 2 | Investigating KYNA production and kynurenergic manipulation on acute mouse brain slice preparations. Brain Res Bull. 2019 Mar;146:185-191. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.